TP53 and hematopoietic and lymphoid cell neoplasm: Moreover, this is in line with clinical studies on p53/mutp53-reactivating compounds like Mdm2-inhibitors or eprenetapopt (APR-246), which have reported clinical responses mostly in patients with hematological cancers [37, 38, 73].